

# Pentagon City Hospital

2455 Army Navy Drive  
Arlington, Virginia 22206

DL-011199\_02

January 11, 1999

U.S Nuclear Regulatory Commission, Region II  
Material Radiation Protection Section  
Atlanta Federal Center  
61 Forsyth Street, SW (Suite 23T85)  
Atlanta, GA 30303

RE: Amendment to NRC radioactive materials license NRC-45-17123-01

Dear Sir:

We are requesting an amendment to our radioactive materials license to make the following change:

- We would like to change the Radiation Safety Officer to Russell E. McWey, M.D. Please note that Dr. McWey meets the qualification requirements, as he is an authorized user of materials for this license.

Additionally, we would like to notify you [under 10CFR 35.13(b)(3)] that we have added several physicians as authorized users of all materials included on this license. Specifically, on this license, these physicians are authorized users of any byproduct material, form, and use identified in 10 CFR 31.11, 35.100 and 35.200, as identified on our materials license. The physicians added to our license as authorized users as described above are: Russell E. McWey, M.D., Joseph A. Backer, M.D., Samuel A. Crimone, M.D., John A. Long, Jr., M.D., Diane Conley, M.D. Please note Drs. McWey, Backer, Crimone, Long, and Conley are all currently identified as authorized users of these byproduct materials on NRC radioactive materials license #45-01099-01 (Columbia Arlington Hospital).

Also, please delete Dr. George C. Soteropoulos as an authorized user on this license.

Please note that the amendment fee for category 7.C. of \$450.00 is enclosed. If you have any questions, please contact Dr. Russell McWey or myself at your convenience.

Sincerely,

  
Thomas E. Anderson, CEO  
President, Chief Executive Officer

258242

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 61

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer by product source and special nuclear material specified below, to use such material for the purposes and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 1b3 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee:

In accordance with letter dated September 24, 1997

1 Columbia Arlington Hospital

2 License Number 45-01099-01

is amended in its entirety to read as follows:

2 1701 North George Mason Drive  
Arlington, Virginia 22205

4 Expiration Date March 31, 2004 (Extended)

5 Docket or Reference No. 030-03303

6 Byproduct Source and/or Special Nuclear Material

7 Chemical and/or Physical Form

8 Maximum Amount that Licensee May Possess at Any One Time Under This License

A. Any byproduct material identified in 10 CFR 35.100

A. Any radiopharmaceutical identified in 10 CFR 35.100

A. As needed

B. Any byproduct material identified in 10 CFR 35.200

B. Any radiopharmaceutical identified in 10 CFR 35.200

B. As needed

C. Any byproduct material identified in 10 CFR 35.300

C. Any radiopharmaceutical identified in 10 CFR 35.300

C. As needed (Not to exceed 10 curies of I-131)

D. Any byproduct material identified in 10 CFR 35.400

D. Any brachytherapy sources identified in 10 CFR 35.400

D. As needed

E. Any byproduct material identified in 10 CFR 35.500

E. Any diagnostic source identified in 10 CFR 35.400 in a compatible device registered pursuant to 10 CFR 32.210

E. As needed

F. Any byproduct material identified in 10 CFR 31.11

F. Prepackaged kits

F. As needed

G. Uranium depleted in Uranium-235

G. Cadmium plated metal

G. As needed

H. Americium 241

H. Sealed Source (Amersham Model No. AMC 24)

H. 14 millicuries

I. Carbon 14

I. Any

I. 1 millicurie

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
**45-01099-01**  
Docket or Reference Number  
**030-03303**

Amendment No. 51

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
  - B. Medical use described in 10 CFR 35.200.
  - C. Medical use described in 10 CFR 35.300.
  - D. Medical use described in 10 CFR 35.400.
  - E. Medical use described in 10 CFR 35.500.
- In vitro studies.  
Shielding in a linear accelerator.  
To be used in Searle Analytic Model SS-10244 Anatomical Marker.  
i. For non-human research as described in attachment to letter dated November 10, 1988.

**CONDITIONS**

10. Location for use: Columbia Arlington Hospital  
1701 North George Mason Drive  
Arlington, Virginia

11. Radiation Safety Officer: Russell E. McWey, M.D.

12. Authorized users:

- A. Glen A. Landis, M.D. for licensed material identified in 10 CFR 35.100, 35.200, 35.300, 35.500, 31.11, Americium 241 anatomical marker, and Carbon 14 for non-human research.
- B. Joseph A. Backer, M.D. for licensed material identified in 10 CFR 35.100, 35.200, 35.500, 31.11 and Americium 241 anatomical marker.
- C. Samuel A. Crimone, M.D. for licensed material identified in 10 CFR 35.100, 35.200, 35.500, 31.11, Americium 241 anatomical marker, and Phosphorus 32 as soluble phosphate for treatment of polycythemia vera, leukemia and bone metastases.
- D. John A. Long, Jr., M.D. for licensed material identified in 10 CFR 35.100, 35.200, 35.500 and 31.11.
- E. Russell E. McWey, M.D. for licensed material identified in 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.
- F. James J. Linn, M.D. for licensed material in 10 CFR 31.11, Iodine 125 as iodinated human serum albumin for determination of blood and blood plasma volume, and Chromium 51 as sodium chromate for determination of red cell volume and red cell survival time.
- G. William Bruce Lundeen, M.D. for licensed material in 10 CFR 35.400 and depleted uranium as shielding material.
- H. Derick A. Hanlan, M.D. for licensed material in 10 CFR 35.400 and depleted uranium as shielding material.
- I. Murat H. Sor, M.D. for licensed material identified in 10 CFR 35.100, 35.200, and 31.11.
- J. Frederick J. Schwab M.D. for licensed material identified in 10 CFR 35.100, 35.200, and 31.11.
- K. Diane Huntington, M.D. for licensed material identified in 10 CFR 35.100, 35.200, and 31.11.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number	45 01099-01
Director or Reference Number	030-03303
Amendment No. 61	

(continued)

**CONDITIONS**

13. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.

The licensee shall maintain records of information important to safe and effective decommissioning at the licensee's facilities listed in Condition 10 per the provision of 10 CFR 30.35(g) until this license is terminated by the Commission.

Except as specifically provided otherwise in the license and as provided in 10 CFR 35.51, the licensee shall conduct its program in accordance with statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated August 11, 1993

B. Letters dated:

- August 3, 1995 (delete Dr. Dolan)
- October 22, 1996 (Change of ownership information)
- March 1, 1996 (extend expiration date in accordance with 10 CFR 30.36)
- January 15, 1997 (change hospital name)
- September 24, 1997 (add authorized users)
- October 28, 1997 (clarification of medical uses)
- November 3, 1997 (additional information regarding Dr. Huntington)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION  
JAY L. HENSON

**NOV 14 1997**

Date \_\_\_\_\_

By

*Jay L. Henson*  
Region II, Division of Nuclear Materials Safety  
11 Forsyth Street, S.W., Suite 23T55  
Atlanta, GA 30303